Geron (NASDAQ:GERN) Downgraded to Sector Perform Rating by Scotiabank

Geron (NASDAQ:GERN - Get Free Report) was downgraded by investment analysts at Scotiabank from a "sector outperform" rating to a "sector perform" rating in a research report issued on Thursday,Briefing.com Automated Import reports. They currently have a $1.50 price objective on the biopharmaceutical company's stock. Scotiabank's target price suggests a potential upside of 14.50% from the company's previous close.

Other equities analysts also recently issued research reports about the company. HC Wainwright reaffirmed a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. Barclays reiterated an "overweight" rating and set a $4.00 price objective (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $5.00 target price on shares of Geron in a research report on Wednesday, March 12th. B. Riley lowered shares of Geron from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $3.50 to $2.00 in a research report on Thursday, February 27th. Finally, Stifel Nicolaus cut their price objective on shares of Geron from $8.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $5.06.

Geron Trading Down 0.8 %

Shares of NASDAQ:GERN opened at $1.31 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The company's 50-day moving average price is $1.51 and its two-hundred day moving average price is $2.77. The stock has a market capitalization of $834.36 million, a PE ratio of -4.09 and a beta of 0.76. Geron has a one year low of $1.17 and a one year high of $5.34.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm had revenue of $39.60 million during the quarter, compared to analysts' expectations of $49.88 million. During the same quarter last year, the company posted ($0.07) earnings per share. The company's revenue for the quarter was up 12927.3% compared to the same quarter last year. On average, equities analysts forecast that Geron will post -0.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Rovin Capital UT ADV lifted its position in Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 3,660 shares in the last quarter. Xponance Inc. grew its stake in Geron by 12.9% during the fourth quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock valued at $150,000 after acquiring an additional 4,829 shares in the last quarter. KBC Group NV grew its holdings in Geron by 45.1% during the 4th quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 7,592 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in Geron during the fourth quarter valued at $28,000. Finally, Lazari Capital Management Inc. lifted its holdings in shares of Geron by 11.7% in the 4th quarter. Lazari Capital Management Inc. now owns 76,424 shares of the biopharmaceutical company's stock valued at $271,000 after acquiring an additional 8,000 shares during the last quarter. 73.71% of the stock is owned by institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.